AR122505A1 - Procesos para preparar un inhibidor de jak1 - Google Patents

Procesos para preparar un inhibidor de jak1

Info

Publication number
AR122505A1
AR122505A1 ARP210101500A ARP210101500A AR122505A1 AR 122505 A1 AR122505 A1 AR 122505A1 AR P210101500 A ARP210101500 A AR P210101500A AR P210101500 A ARP210101500 A AR P210101500A AR 122505 A1 AR122505 A1 AR 122505A1
Authority
AR
Argentina
Prior art keywords
prepare
processes
jak1 inhibitor
compound
jak1
Prior art date
Application number
ARP210101500A
Other languages
English (en)
Inventor
Jiacheng Zhou
Yingrui Dai
Zhongjiang Jia
Yongchun Pan
James M Parks
Anthony J Tomaine
Jianji Wang
Aibin Zhang
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AR122505A1 publication Critical patent/AR122505A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/26—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24
    • B01J31/28—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24 of the platinum group metals, iron group metals or copper

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Reivindicación 1: Un proceso para preparar (base libre del Compuesto 1) o una sal de este, caracterizado porque comprende hacer reaccionar (Compuesto 1x) con (Compuesto 2x) para formar la base libre del Compuesto 1, o una sal de este.
ARP210101500A 2020-06-02 2021-06-02 Procesos para preparar un inhibidor de jak1 AR122505A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063033618P 2020-06-02 2020-06-02

Publications (1)

Publication Number Publication Date
AR122505A1 true AR122505A1 (es) 2022-09-14

Family

ID=76601838

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101500A AR122505A1 (es) 2020-06-02 2021-06-02 Procesos para preparar un inhibidor de jak1

Country Status (17)

Country Link
US (1) US11685731B2 (es)
JP (1) JP2023528868A (es)
KR (1) KR20230027086A (es)
CN (1) CN115836065A (es)
AR (1) AR122505A1 (es)
AU (1) AU2021283271A1 (es)
BR (1) BR112022024632A2 (es)
CA (1) CA3184275A1 (es)
CL (1) CL2022003363A1 (es)
CO (1) CO2022017344A2 (es)
CR (1) CR20220612A (es)
EC (1) ECSP22091930A (es)
IL (1) IL298118A (es)
MX (1) MX2022015221A (es)
PE (1) PE20231102A1 (es)
TW (1) TW202210471A (es)
WO (1) WO2021247668A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3231801T3 (pl) 2013-05-17 2019-07-31 Incyte Corporation Sol bipirazolu jako inhibitor jak
BR112020016628A2 (pt) 2018-02-16 2020-12-15 Incyte Corporation Inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
KR20230118118A (ko) 2020-12-08 2023-08-10 인사이트 코포레이션 백반증의 치료를 위한 jak1 경로 저해제

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
HU230396B1 (hu) 2000-06-28 2016-04-28 Smithkline Beecham Plc Nedves őrlési eljárás
CA2466243A1 (en) 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
NZ532136A (en) 2001-10-30 2006-08-31 Novartis Ag Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
MX2007006204A (es) 2004-11-24 2007-06-20 Novartis Ag Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa.
UA116187C2 (uk) 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
ES2714092T3 (es) 2007-06-13 2019-05-27 Incyte Holdings Corp Uso de sales del inhibidor de quinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
UA104849C2 (uk) 2007-11-16 2014-03-25 Інсайт Корпорейшн 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
PT2288610T (pt) 2008-03-11 2016-10-17 Incyte Holdings Corp Derivados de azetidina e de ciclobutano como inibidores de jak
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
UA106078C2 (uk) 2009-05-22 2014-07-25 Інсайт Корпорейшн 3-[4-(7H-ПІРОЛО[2,3-d]ПІРИМІДИН-4-ІЛ)-1H-ПІРАЗОЛ-1-ІЛ]ОКТАН- АБО ГЕПТАННІТРИЛ ЯК JAK-ІНГІБІТОРИ
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2486041B1 (en) 2009-10-09 2013-08-14 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
WO2011103423A1 (en) 2010-02-18 2011-08-25 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
TWI643857B (zh) 2010-03-10 2018-12-11 英塞特公司 作為ｊａｋ１抑制劑之哌啶-４-基三亞甲亞胺衍生物
KR20130094710A (ko) 2010-04-14 2013-08-26 어레이 바이오파마 인크. Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
JP5917545B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
US8828987B2 (en) 2010-12-10 2014-09-09 Rottapharm Biotech S.R.L. Pyridine amide derivatives as EP4 receptor antagonists
EP2678686B1 (en) 2011-02-24 2017-10-11 Massachusetts Institute of Technology ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
JP6014149B2 (ja) 2011-09-22 2016-10-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヤヌスキナーゼ阻害剤としての非環式シアノエチルピラゾール
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
CN104918945B (zh) 2012-11-01 2018-01-05 因赛特公司 作为jak抑制剂的三环稠合噻吩衍生物
NZ748448A (en) 2012-11-15 2019-12-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
TWI634121B (zh) 2013-03-06 2018-09-01 英塞特控股公司 用於製備ｊａｋ抑制劑之方法及中間物
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
JP6533217B2 (ja) 2013-05-17 2019-06-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の治療および予防のための６−架橋ヘテロアリールジヒドロピリミジン類
PL3231801T3 (pl) 2013-05-17 2019-07-31 Incyte Corporation Sol bipirazolu jako inhibitor jak
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
KR20220103810A (ko) 2013-08-07 2022-07-22 인사이트 코포레이션 Jak1 억제제용 지속 방출 복용 형태
JP6576941B2 (ja) 2014-02-28 2019-09-18 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ 骨髄異形成症候群の治療のためのｊａｋ１阻害剤
CR20160553A (es) 2014-04-30 2017-04-25 Incyte Corp Procesos para preparar un inhibidor de jak1 y nuevas formas de este
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
LT3233843T (lt) 2014-12-16 2019-12-10 Novartis Ag Izoksazolo hidroksamido rūgšties junginiai, kaip lpxc inhibitoriai

Also Published As

Publication number Publication date
CO2022017344A2 (es) 2023-03-07
WO2021247668A1 (en) 2021-12-09
US20210380563A1 (en) 2021-12-09
ECSP22091930A (es) 2023-02-28
PE20231102A1 (es) 2023-07-19
TW202210471A (zh) 2022-03-16
CR20220612A (es) 2023-04-11
KR20230027086A (ko) 2023-02-27
MX2022015221A (es) 2023-03-08
BR112022024632A2 (pt) 2023-02-28
JP2023528868A (ja) 2023-07-06
CA3184275A1 (en) 2021-12-09
US11685731B2 (en) 2023-06-27
EP4157831A1 (en) 2023-04-05
CN115836065A (zh) 2023-03-21
AU2021283271A1 (en) 2022-12-15
CL2022003363A1 (es) 2023-05-19
IL298118A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
AR122505A1 (es) Procesos para preparar un inhibidor de jak1
CO2022002637A2 (es) Proceso de fabricación de moduladores de cftr
CO2022010317A2 (es) Inhibidores de egfr
CL2020000407A1 (es) Proceso para preparar compuesto inhibidor de bet. (solicitud divisional 201803702).
AR118707A1 (es) Inhibidores de la proteasa del vih
EA201991697A1 (ru) Сульфоксиминовые ингибиторы гликозидазы
EA202193015A1 (ru) Ингибиторы cdk
AR111960A1 (es) Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
CL2023000482A1 (es) Proceso e intermediarios para preparar un inhibidor de jak1.
AR116951A1 (es) Sales cristalinas de un inhibidor de calicreína plasmática
UY39832A (es) Inhibidores de cdk2
CO2018007008A2 (es) "procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo"
AR110527A1 (es) Proceso para la preparación de compuestos de benzoxazepina oxazolidinona
MX2020011671A (es) Nuevo proceso para la preparacion de diamidas antranilicas.
MX2017015662A (es) Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac).
BR112022026981A2 (pt) Processos para a preparação de um composto e processo para a síntese de um composto
CO2023003281A2 (es) Proceso e intermediarios para preparar un inhibidor de jak
BR112023000350A2 (pt) Sais e formas de um inibidor de wee1
CL2023001760A1 (es) Proceso
BR112023018246A2 (pt) Formas de sal e sólidas de um inibidor de cinase
CL2021002300A1 (es) Procedimiento para la preparación de 4-amino-5-metilpiridona
WO2020128020A3 (de) Verfahren zur herstellung von 2-alkoxy-4-amino-5-methyl-pyridinen und/oder von 2-alkoxy-4-alkylamino-5-methyl-pyridinen
CO2022008127A2 (es) Procesos e intermediario para la preparación de oxetan-2-ilmetanamina
MX2023006157A (es) Mediadores lipidicos proresolutivos especializados para el tratamiento del pcos.